Skip to main content
Premium Trial:

Request an Annual Quote

Hedera Dx Hedera Profiling 2 ctDNA Test Panel

Hedera Dx has launched a disseminated blood based cancer test kit, called the Hedera Profiling 2 ctDNA Test Panel, intended to help larger patient populations access precision cancer therapies. The firm said that its fully streamlined solution, a combination of laboratory reagents and interpretation software, allows hospitals to adopt liquid biopsy testing locally for their patients with minimal internal effort. The in-house test kits offer an alternative to various available send-out tests performed in centralized commercial laboratories. Assays cover over 80 percent of the ESMO Scale for Clincal Actionability of molecular Targets (ESCAT)  Level I genes. The wet lab component of the assay is coupled with the firm's Hedera Prime, a registered IVD medical device platform to rapidly interpret DNA sequencing results and quickly generate clinical reports